THE INVESTOR

메뉴열기
September 21, 2019

Celltrion establishes Irish unit to expand in European biosimilar market

PUBLISHED : August 20, 2019 - 15:22

UPDATED : August 20, 2019 - 15:26

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20.

At the new unit, the Korean company plans to mainly conduct clinical trials to prove the safety of its biosimilars to local medical staff, and also prepare for sales after achieving the European Medicines Agency’s approval.




Celltrion has finished the stage 3 clinical trial of its biosimilar Remsima SC in Europe and is waiting for approval from European authorities for the sale. 

Remsima SC is a subcutaneous version of Remsima, the Korean company’s biosimilar of Johnson & Johnson’s autoimmune disease therapy Remicade. According to the company, the new pen-type Remsima will enable patients to inject the therapy by themselves without visiting a hospital.

Celltrion has been adding more overseas units to diversify its foreign retail channel, which is mostly done through its affiliate Celltrion Healthcare, in a move to directly sell the group’s biosimilar products. Recently, Celltrion also announced that it has established the joint venture Vcell Healthcare in Shanghai with Hong Kong-based conglomerate Nan Fung Group to make a foray into China.

By Song Seung-hyun (ssh@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.